U.S. health regulators on Thursday delayed approval of Teva Pharmaceutical Industries Ltd's biotechnology medicine to boost white blood cells that is similar to Amgen Inc's big-selling Neupogen.
The U.S. Food and Drug Administration issued a complete response letter seeking "several items" related to Teva's drug, known as Neutroval, as a treatment for cancer patients undergoing chemotherapy, the Israel-based company said in a statement.
If the Teva drug were launched commercially in the United States, it would be the first competitor in the country for Amgen's Neupogen, which had U.S. sales of $225 million in the second quarter. Teva has already been selling the drug, also known as XM02, under the name TevaGrastim in several European countries.
•CLICK HERE to read the Reuters story.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- Amgen Competitor Gets Drug Approval
- Amgen Says Infection Drug Patent Dispute Settled in its Favor
- Amgen Loses Bid to Halt Biosimilar
- FDA Approves Biosimilar, Amgen's Rival
- Amgen's Competitor Launches Neupogen Knockoff
- FDA Panel Approves Rival Neupogen Drug
- Amgen Continues Protecting Its Hold on Biotech Products
- Amgen Granted Novartis Injunction